De novo protein design
Proteins specified on a computer and realized in a lab — backbone geometry, binding interfaces and self-assembly designed from physical principles rather than found in nature. The table carries two institutions with fully sourced dossier ledgers; the field's well-funded companies are named in the note, not padded into the table.
1 · What it gives
De novo protein design inverts the relationship between biology and engineering that held for the whole molecular age: instead of finding a protein that does something and improving it, the designer specifies the function — bind this target, catalyze that reaction, self-assemble into this cage — and computes a sequence that folds into a structure performing it. The discipline stands on a physical claim proven repeatedly since its founding demonstrations: that the mapping from amino-acid sequence to folded structure is computable, so a backbone never seen in nature can be specified, produced by solid-phase or recombinant synthesis, and verified against its design model by X-ray crystallography or cryo-EM. The Institute for Protein Design at the University of Washington — the field’s center of gravity under David Baker — runs this loop as an institution: a $33 million annual research budget, a $7 million grant from the Washington Research Foundation in 2026, core laboratories spanning protein production, peptide synthesis, electron and light microscopy and X-ray crystallography, more than 250 members, 50-plus scientific publications per year and over 100 patents issued. The applied output is already a product class — designed vaccines, binders and self-assembling nanomaterials — and the discipline’s industrialization runs through synthetic-biology manufacturing on the other side of the Pacific: Tianjin University’s School of Synthetic Biology and Biomanufacturing, home to the State Key Laboratory of Synthetic Biology, ranks first globally in synthetic-biology research papers in Scopus and trains roughly 2,000 postgraduates.
Key directions of de novo protein design:
- Computational backbone and interface design (Design-Build-Test): specified geometry computed from physical principles, synthesized, and verified against the design model by crystallography or cryo-EM — the core loop the Institute for Protein Design runs across 50-plus publications a year on a $33 million annual budget.
- Designed vaccines and therapeutics (Function by Specification): immunogens, binders and therapeutic candidates designed rather than discovered, moving through the ATMP and biologics frameworks that the FDA, EMA and NMPA operate.
- Self-assembling nanomaterials (Protein Architectures): designed cages, lattices and arrays whose assembly is programmed by the sequence itself — the materials wing of the discipline.
- Genome-scale synthesis as the manufacturing arm (Synthetic Biology Institutes): the design-build-test loop at chromosome and genome scale — Tianjin University’s yeast genome synthesis work anchors the synthesis-and-assembly layer that turns designs into buildable biology.
Sectoral value chain#
[function specification] ──> [computational design] ──> [gene synthesis, expression]
│
(structure-function verification)
│
▼
[product, material, therapy] <── [scale-up biomanufacturing] <── [designed protein validated]
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Function specification | binding, catalysis or assembly target | In: therapeutic or material need. Out: design brief. |
| Computational design | backbone, interface and sequence computation | In: design brief, structure models. Out: designed amino-acid sequences. |
| Synthesis and expression | gene synthesis and recombinant production | In: designed sequences. Out: designed proteins in the lab. |
| Verification | structure and function against the model | In: designed proteins. Out: crystallography/cryo-EM-verified designs. |
| Iterative optimization | design cycles folding experiment back into model | In: verification data. Out: improved design generations. |
| Biomanufacturing | scale-up to product volumes | In: verified designs. Out: therapies, vaccines, materials at scale. |
Cross-cutting technologies of the sector:
- Structure prediction networks (Computed Folds): the models that made backbone computation tractable, now the substrate design iterates on.
- Gene synthesis and DNA fabrication (Build Layer): the industrial synthesis that turns sequences into expressible constructs at design-loop speed.
- Cryo-EM and high-throughput characterization (Test Layer): the verification instruments that close the design loop.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 6 steps
- 1Function specificationThe need — bind a target, catalyze a reaction, assemble into a cage — is written as a design brief with quantitative acceptance criteria.
- 2Computational designData, software & automationBackbone geometry, interfaces and sequences are computed; the Institute for Protein Design’s pipeline is the reference implementation of this stage as an institutional process.Who can do this step matched automatically163,050 tonnes“As the fundamental component of 5G deployment, optic fibre is critical to making Hong Kong a smart city and laying the groundwork for IoT.”PBS Biotech United States✓ ISO 9001 industrial scale“PBS-3 Vertical-Wheel Bioreactor Software 3.0 (21 CFR Part 11 cGMP Upgrade)”MIRAI Japanindustrial scale“It also runs IoT/“SensorCorpus” software for monitoring/optimization, and its cultivation tech has been described as LED/water/airflow method optimization (e.g., “heavy lettuce”); …”
- 3Gene synthesis and expressionSynthesis & conversionDesigned sequences are synthesized to order and expressed recombinantly — Tianjin University’s national facility stack is the industrial form of this stage at genome scale.Who can do this step matched automatically163,050 tonnes“Uniquely equipped with the credentials for the R&D, design, and production of both high-efficiency dust filtration materials and SCR denitration catalysts, as well as for the …”Rossari Biotech (NSE) India✓ ISO 9001 industrial scale“A liver protectant comprising a combination of Liver extracts, Choline chloride, Inositol, Vitamin B12, Protein Hydrolysate, Biotin, Selenium, Vitamin E and Methylsulfonylmethane.”Sea6 Energy Indiaindustrial scale“Core technology includes an in-house full-stack farming automation platform (SeaCombine, automated seeding/harvesting, data dashboards, weather/drone monitoring) and a …”“2026-06-28 [BIOCATALYST LEADERSHIP: How Enzymes are Propelling India's Pharma Bio Spectrum - business - Read this story on Magzter.com — A brief mention of Aum Enzymes or Infinita …”SyncoZymes (Shanghai) China1,200 tons industrial scale“is a biotechnology company specializing in green pharmaceutical technology, biocatalysis, and synthetic biology.”
- 4Structural verificationTesting & analyticsExpressed proteins are verified against design models by cryo-EM or X-ray crystallography — the institute’s core labs keep verification inside the design loop rather than after it.Who can do this step matched automaticallyRovita GmbH Germany“As an accredited laboratory, our partner Focus Foodlabs offers extensive services in the field of food analysis and food safety.”industrial scale“ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
- 5Iterative optimizationVerification data feeds the next design generation — the cycle that turns single successful designs into designable families.
- 6Scale-up biomanufacturingContract manufacturing (CMO/CDMO)Verified designs move to recombinant production and, for therapeutics, through the FDA, EMA ATMP or NMPA frameworks that turn a computed sequence into a licensed product.Who can do this step matched automaticallyCell AgriTech Malaysia5,000 L industrial scale“At Cell AgriTech, we position ourselves as Asia’s first dedicated CDMO for cultivated meat and plant cell culture.”HLB Genex (ex-GenoFocus) South Koreaindustrial scale“Custom protein development and manufacturing: CDMO services with in-house contract manufacturing facilities for new protein development.”“Aum Enzymes (aumenzymes.com) is a small, unfunded enzyme manufacturer in India (Anand; LinkedIn also lists Borsad) producing industrial enzymes and custom enzyme solutions via …”ScaleUp Bio Singapore10,000 L pilot scale“ScaleUp Bio is a Singapore-based CDMO specializing in precision fermentation for food, nutrition, and specialty bio-based ingredients.”
4 · Who delivers
Matched suppliers (matched automatically)
| Amai Proteins | Israel | Producer | active |
| Liying Biotech 粒影生物 | China | Producer | active |
| General Poultry Company B.S.C. | Bahrain | Producer | active |
| veritree | Canada | Equipment | active |
| Helaina | United States | Producer | active |
| Novo Nordisk | Denmark | Producer | active |
| AMSilk | Germany | Equipment | active |
| Nature's Fynd | United States | Producer | active |
| Grassa | Netherlands | Producer | active |
| Perfect Day | United States | Producer | active |
| 21st.BIO | Denmark | Producer | active |
| Shuangta Food 双塔食品 (SZ 002481) | China | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Institute for Protein Design | 🇺🇸 USA | Design-build-test of novel proteins | David Baker-directed; $33 m/yr budget + $7 m WRF grant (2026); 250+ members; 50+ papers/yr; 100+ patents | Unknown |
| Tianjin University | 🇨🇳 China | Synthetic biology school and State Key Lab | Yeast genome synthesis; No. 1 globally in Scopus synthetic-biology papers; ~2,000 postgraduates trained; national facility stack | Research |
5 · Rules & route to market
United States
The US hosts the field’s institutional center of gravity and its venture layer; the design loop’s published output and patent estate are American in majority.
The Baker-lab institute, patent estate, designed therapeutics pipeline#
- Institute for Protein Design (University of Washington): housed within the School of Medicine, directed by David Baker, with 250+ members, a $33 million annual research budget and a $7 million Washington Research Foundation grant in 2026, core R&D labs for protein production, peptide synthesis, electron and light microscopy and X-ray crystallography, 50-plus publications per year and 100-plus patents issued.
- Design of vaccine and therapeutic candidates: the institute’s research focus spans de novo protein design, computational biomolecular design, vaccine and therapeutic development and self-assembling systems — the pipeline venture companies license from.
- FDA pathway for designed biologics: designed protein therapeutics file as biologics under FDA review — the regulatory classification that turns a computed sequence into a licensable product.
European Union
Europe contributes the ATMP regulatory framework that designed-protein therapeutics file under and a growing computational-design academic layer.
ATMP framework for designed proteins, European design groups, regulator readiness#
- EMA’s ATMP framework (Regulation EC No 1394/2007): designed-protein therapeutics and vaccines file under the advanced-therapy regime the EU pioneered — the classification that gives the field’s outputs a European regulatory route.
- Academic design groups across member states: European structural-biology and computational-design groups feed the field’s method base, with cryo-EM facilities among the strongest verification infrastructures anywhere.
- Regulator readiness as a field asset: a mature ATMP pathway means a designed therapeutic has a defined route to European patients — the institutional half of translation that pure software fields lack.
China
China industrializes the synthesis-and-build arm of the discipline at university-institute scale, with Tianjin University the anchor institution by publication volume and training throughput.
Tianjin University’s synthetic biology complex, genome synthesis, talent throughput#
- School of Synthetic Biology and Biomanufacturing (Tianjin University): home to the State Key Laboratory of Synthetic Biology, the Frontier Science Center for Synthetic Biology and the Key Laboratory of Systems Bioengineering — a stack of national facilities dedicated to the build side of the design loop.
- Genome-scale synthesis: research spanning yeast genome synthesis, DNA information storage and artificial cell construction — the chromosome-scale end of the build layer that makes designed genomes constructible.
- Publication and talent throughput: first globally in synthetic-biology research papers in Scopus, with 20 senior national-level leading talents, 37 national-level young talents and roughly 2,000 postgraduates trained as of 2022 — the workforce the design discipline scales through.
6 · Money: tenders & grants
| Grant | Circular innovative advanced materials: facilitating the transition from design to markets (RIA) (Innovative … European Commission · EU | Feb 2, 2027 71 days |
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 141 days |
7 · Tech stack & innovations
The stack is a loop — specify, compute, build, verify — and its innovations are the instruments that shortened the loop from years to weeks.
- Computational structure and interface design (Specify-to-Sequence):
- backbone geometry and binding interfaces are computed from physical principles; the output is an amino-acid sequence that has never existed.
- case: the Institute for Protein Design’s design-build-test loop — 50-plus publications per year, 100-plus patents issued, self-assembling systems among its research focuses.
- Gene synthesis and genome-scale construction (Build at Scale):
- designed sequences become expressible constructs through commercial and institute gene synthesis; at chromosome scale, whole genomes are synthesized and assembled.
- case: Tianjin University’s yeast genome synthesis program inside the State Key Laboratory of Synthetic Biology.
- High-throughput structural verification (Close the Loop):
- cryo-EM and X-ray crystallography verify designed structures against their models — the step that keeps design honest.
- case: the institute’s core labs span protein production, peptide synthesis, electron and light microscopy and X-ray crystallography in one facility stack.
Sources 2 · 0 independent · 2 producer sites
Producers' own sites 2
- research.washington.edu · www.ipd.uw.edu · www.ipd.uw.edu · www.ipd.uw.edu · www.ipd.uw.edu producer checked 2026-09-18
- en.tju.edu.cn · en.tju.edu.cn · global.chinadaily.com.cn · synbm.tju.edu.cn · synbm.tju.edu.cn producer checked 2026-09-18